Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 257

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 257
---
 budget of            
 approximately $2,680 (EURO 2,185 thousand), out of which $1,095 (EURO 983 thousand) was received in 2019 and $1,039 (EURO 874 thousand) 
 was received in 2021. As of December 31, 2023, the Company, recorded the amount received as a grant liability in other accounts payable 
 in balance sheets.                                                                                                                      
 In April 2024, the Company submitted the                                                                                                
 final report to the Programme and received a notification that the Programme was completed and also received the remaining grant        
 funds at the amount of approximately $350 (EURO 327 thousands). Following the completion of the Programme, the Company recorded all     
 of the grant amount received as a reduction in research and development expenses.                                                       |

| 5. | In January 2024, the Company                                                                                                            
 renewed its facility lease agreement until December 2024. The monthly rental obligations under non-cancellable leases are approximately 
 $5.5 (including $3 for administrative expenses).                                                                                        |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

<div align='center'>F-13</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

Future minimum lease payments under non-cancelable
operating leases as of June 30, 2024 are as follows:

| 2024 |     | USD | 33 |
|:-----|:----|:----|---:|
|      |     | $   | 33 |

The Company elected to apply the practical
expedients permitted under the transition guidance in ASU 2016-02, and the Company also elected not to apply the recognition requirements
in ASU 2016-02 to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s
financial statements as a result of adopting ASU 2016-02.

| 6. | In 2019, a controversy has                                                                                                              
 arisen between the Company and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments